Jason Kantor Recent News
The Medicines Company Surges Amid Credit Suisse Upgrade
UPDATE: Credit Suisse Downgrades Cubist Pharmaceuticals On Execution Risk To Global Expansion Of Hospital Franchise
XOMA Corp Volatile Amid Differing Analyst Reports
Credit Suisse Expects New Pricing To Boost Sales For Ariad Pharmaceuticals
UPDATE: Credit Suisse Reiterates On Esperion Therapeutics Inc On Multiple Positive Factors
Credit Suisse Sees Continued Operational Progress For Kite Pharma
UPDATE: Credit Suisse Reiterates On BIND Therapeutics After AMGN Declines Option On Accurin Technology
Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics
UPDATE: Credit Suisse Initiates On Alder Biopharmaceuticals, Optimistic On 'Derisked' Assets
UPDATE: Credit Suisse Downgrades The Medicines Company Following Negative Cangrelor Panel
Credit Suisse Reports Ariad's Iclusig is 'Essential Drug'
Credit Suisse Maintains on Cubist Pharmaceuticals
UPDATE: Credit Suisse Raises PT on Ariad Pharmaceuticals, View Remains Cautious
UPDATE: Credit Suisse Reiterates on Ariad Pharmaceuticals as Iclusig Re-Launch is Expected to be Bumpy
UPDATE: Credit Suisse Raises PT on Prothena Following Deal with Roche
UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on Limited Clinical News in 2014
UPDATE: Credit Suisse Initiates PTC Therapeutics at Outperform on Bullish Thesis
UPDATE: Credit Suisse Downgrades Spectrum Pharmaceuticals on Limited Growth Opportunities and Increased Risk
UPDATE: Credit Suisse Initiates Portola Pharmaceuticals at Outperform Rating Ahead of PIII APEX Trial